Rachel Galot

Brussels, BRU, Belgium

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 28 publications

Phase I safety, efficacy, and biomarker response evaluations of three oral PD-L1 inhibitors: INCB086550, INCB099280, and INCB099318.

Phase I safety, efficacy, and biomarker response evaluations of three oral PD-L1 inhibitors: INCB086550, INCB099280, and INCB099318.

Journal: Journal for immunotherapy of cancer

Published: July 27, 2026

Circulating tumor DNA in human papilloma virus negative head and neck squamous cell carcinoma.

Circulating tumor DNA in human papilloma virus negative head and neck squamous cell carcinoma.

Journal: Current opinion in oncology

Published: March 06, 2026

Safety and efficacy of sotorasib plus panitumumab and FOLFIRI for previously treated KRAS G12C-mutated metastatic colorectal cancer in the CodeBreaK 101 phase Ib study.

Safety and efficacy of sotorasib plus panitumumab and FOLFIRI for previously treated KRAS G12C-mutated metastatic colorectal cancer in the CodeBreaK 101 phase Ib study.

Journal: ESMO open

Published: February 15, 2026

Case Report: Cardiac metastasis from urothelial carcinoma with predominant squamous differentiation in a young woman: first reported case treated with enfortumab vedotin plus pembrolizumab.

Case Report: Cardiac metastasis from urothelial carcinoma with predominant squamous differentiation in a young woman: first reported case treated with enfortumab vedotin plus pembrolizumab.

Journal: Frontiers in oncology

Published: January 12, 2026

Correction: A case report of malignant hypertension and multiorgan dysfunction during immunotherapy for gallbladder cancer.

Correction: A case report of malignant hypertension and multiorgan dysfunction during immunotherapy for gallbladder cancer.

Journal: Frontiers in oncology

Published: December 18, 2025

State of the art and future directions in the treatment of metastatic adenoid cystic carcinoma.

State of the art and future directions in the treatment of metastatic adenoid cystic carcinoma.

Journal: Current opinion in oncology

Published: November 12, 2025

Molecular and Immune Landscape of Recurrent and/or Distant Metastatic Squamous Cell Carcinoma of the Head and Neck: An EORTC/IMMUCAN Project.

Molecular and Immune Landscape of Recurrent and/or Distant Metastatic Squamous Cell Carcinoma of the Head and Neck: An EORTC/IMMUCAN Project.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: September 11, 2025

Genomic and Immune Landscape of Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Progressing on Anti-PD-1 Treatment.

Genomic and Immune Landscape of Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Progressing on Anti-PD-1 Treatment.

Journal: Cancer immunology research

Published: August 07, 2025

A case report of malignant hypertension and multiorgan dysfunction during immunotherapy for gallbladder cancer.

A case report of malignant hypertension and multiorgan dysfunction during immunotherapy for gallbladder cancer.

Journal: Frontiers in oncology

Published: July 02, 2025

Tumor-Informed ctDNA Assay to Predict Outcome in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Treated with PD-1 Inhibitor.

Tumor-Informed ctDNA Assay to Predict Outcome in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Treated with PD-1 Inhibitor.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: April 25, 2025

Safety and Antitumor Activity of a Novel aCD25 Treg Depleter RG6292 as a Single Agent and in Combination with Atezolizumab in Patients with Solid Tumors.

Safety and Antitumor Activity of a Novel aCD25 Treg Depleter RG6292 as a Single Agent and in Combination with Atezolizumab in Patients with Solid Tumors.

Journal: Cancer research communications

Published: January 02, 2025

A phase II study of monalizumab and durvalumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: results of the I2 cohort of the EORTC-HNCG-1559 trial (UPSTREAM).

A phase II study of monalizumab and durvalumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: results of the I2 cohort of the EORTC-HNCG-1559 trial (UPSTREAM).

Journal: ESMO open

Published: December 23, 2024

Showing 1-12 of 28

Last Updated: 09/26/2026